Published in Genomics and Genetics Weekly, October 5th, 2001
The transaction unites Eos' drug target identification and validation expertise and therapeutic antibody development skills with Pharmacopeia's integrated small-molecule drug discovery capabilities. The combined technologies will create a powerful platform for the identification and validation of drug targets and the discovery of small-molecule and therapeutic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Genomics and Genetics Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.